Portal de Periódicos da CAPES

Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects

1972; Elsevier BV; Volume: 17; Issue: 3 Linguagem: Inglês

10.1016/0022-510x(72)90030-5

1878-5883

Douglas Jones, M J Turnbull, J. A. R. Lenman, Murray Robertson,

Treatment of Major Depression

The urinary excretion of several monoamines and metabolites was determined in Parkinsonian patients immediately prior to, and during the first 4 days of amantadine (200 mg daily) therapy. Amantadine produced a statistically-significant increase in the excretion of 1,4-methylhistamine and 5-hydroxyindole-3-acetic acid. There was also a tendency towards a higher dopamine and homovanillic acid excretion. These findings suggest that amantadine increases the release of monoamines and this may be the basis of its beneficial effect in Parkinson's disease. In contrast to these observations, amantadine did not affect the urinary amine excretion pattern in volunteer subjects. Possible reasons for this difference are discussed. Levodopa or levodopa/amantadine produced the expected increase in urinary dopamine and homovanillic acid excretions but also significantly reduced the excretion of 5-hydroxyindole-3-acetic acid.